A Randomized, Multicenter, Single Blind Study in Men With Metastatic Androgen Independent Prostate Cancer to Evaluate Sipuleucel-T Manufactured With Different Concentrations of PA2024 Antigen.

Trial Profile

A Randomized, Multicenter, Single Blind Study in Men With Metastatic Androgen Independent Prostate Cancer to Evaluate Sipuleucel-T Manufactured With Different Concentrations of PA2024 Antigen.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 May 2017

At a glance

  • Drugs Sipuleucel-T (Primary)
  • Indications Prostate cancer
  • Focus Pharmacodynamics
  • Acronyms ProACT
  • Sponsors Dendreon Corporation
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 May 2014 According to a Dendreon Corporation media release, the results of this and two other trials (700007675 and 700195649) will be presented at the 2014 American Urological Association Annual Meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top